Japanese drug maker Takeda Pharmaceuticals Co. is hoping an $800 million acquisition of U.S. gout treatment maker URL Pharma Inc. will boost the company’s U.S. sales and, ideally, cover ground lost with its blockbuster type 2 diabetes drug Actos. Not only does Actos lose its patent protection later this year, paving the way for generic competition, sales of the drug have slumped since last year, when the Food and Drug Administration (FDA) warned that studies have linked the diabetes treatment to bladder cancer. Takeda is Japan’s largest drug maker, but the majority of its sales come from the United States ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.